71.21 USD
-0.61 (-0.85%)
71.21 USD
0 (0%)
Taking everything into account, HALO scores 7 out of 10 in our fundamental rating. HALO was compared to 528 industry peers in the Biotechnology industry. HALO scores excellent on profitability, but there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: HALO is growing strongly while it also seems undervalued. These ratings would make HALO suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
- In the past year HALO was profitable.
- HALO had a positive operating cash flow in the past year.
- In the past 5 years HALO has always been profitable.
- In the past 5 years HALO always reported a positive cash flow from operatings.
1.2 Ratios
- HALO's Return On Assets of 26.81% is amongst the best of the industry. HALO outperforms 97.73% of its industry peers.
- Looking at the Return On Equity, with a value of 118.17%, HALO belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
- The Return On Invested Capital of HALO (42.77%) is better than 99.24% of its industry peers.
- HALO had an Average Return On Invested Capital over the past 3 years of 17.81%. This is in line with the industry average of 18.28%.
- The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
- HALO's Profit Margin of 47.91% is amongst the best of the industry. HALO outperforms 98.11% of its industry peers.
- HALO's Profit Margin has declined in the last couple of years.
- HALO has a Operating Margin of 59.33%. This is amongst the best in the industry. HALO outperforms 99.81% of its industry peers.
- In the last couple of years the Operating Margin of HALO has declined.
- HALO has a Gross Margin of 84.55%. This is amongst the best in the industry. HALO outperforms 87.12% of its industry peers.
- In the last couple of years the Gross Margin of HALO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
- HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- HALO has less shares outstanding than it did 1 year ago.
- HALO has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, HALO has an improved debt to assets ratio.
2.2 Solvency
- HALO has an Altman-Z score of 5.19. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.19, HALO is in the better half of the industry, outperforming 73.30% of the companies in the same industry.
- HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
- HALO has a Debt to FCF ratio of 2.51. This is amongst the best in the industry. HALO outperforms 93.37% of its industry peers.
- A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
- With a Debt to Equity ratio value of 1.59, HALO is not doing good in the industry: 76.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.19 |
ROIC/WACC5.41
WACC7.91%
2.3 Liquidity
- A Current Ratio of 1.59 indicates that HALO should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.59, HALO is doing worse than 79.92% of the companies in the same industry.
- A Quick Ratio of 1.37 indicates that HALO should not have too much problems paying its short term obligations.
- HALO's Quick ratio of 1.37 is on the low side compared to the rest of the industry. HALO is outperformed by 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 48.55% over the past year.
- HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
- Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
- The Revenue has been growing by 38.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
- HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.78% yearly.
- HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.23% yearly.
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y32.08%
EPS Next 5Y17.78%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.48%
Revenue Next 5Y13.23%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 12.65, HALO is valued correctly.
- Compared to the rest of the industry, the Price/Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.97% of the companies listed in the same industry.
- HALO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.47.
- HALO is valuated reasonably with a Price/Forward Earnings ratio of 8.59.
- Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.86% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.26, HALO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.65 | ||
| Fwd PE | 8.59 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.59% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.97% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.9 | ||
| EV/EBITDA | 10.95 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of HALO may justify a higher PE ratio.
- HALO's earnings are expected to grow with 32.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y40.02%
EPS Next 3Y32.08%
5. Dividend
5.1 Amount
- No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
71.21
-0.61 (-0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)N/A N/A
Inst Owners105.85%
Inst Owner Change0.92%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap8.37B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76
Price Target77.52 (8.86%)
Short Float %10.75%
Short Ratio5.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)0%
PT rev (3m)1.84%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)1.25%
EPS NY rev (1m)0%
EPS NY rev (3m)1.77%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.65 | ||
| Fwd PE | 8.59 | ||
| P/S | 6.74 | ||
| P/FCF | 13.9 | ||
| P/OCF | 13.71 | ||
| P/B | 16.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.95 |
EPS(TTM)5.63
EY7.91%
EPS(NY)8.29
Fwd EY11.65%
FCF(TTM)5.12
FCFY7.19%
OCF(TTM)5.2
OCFY7.3%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.25
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.19 |
F-Score8
WACC7.91%
ROIC/WACC5.41
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y32.08%
EPS Next 5Y17.78%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.48%
Revenue Next 5Y13.23%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.25%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
Can you provide the valuation status for HALOZYME THERAPEUTICS INC?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.
Can you provide the expected EPS growth for HALO stock?
The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 51.29% in the next year.